Bristol Myers posts long-term Phase 3 data for schizophrenia drug Cobenfy
Bristol Myers Squibb (NYSE:BMY) said its newly approved schizophrenia therapy, Cobenfy, improved disease symptoms with a well ...
Bristol Myers Stock Rises. The Drugmaker Hiked Guidance After Sales Beat.
The pharmaceutical company posted third-quarter adjusted earnings a share of $1.80 on revenue of $11.9 billion.
Bristol Myers’s stock pops as earnings top estimates and company raises guidance
Princeton, N.J.-based Bristol Myers BMY had net income of $1.2 billion, or 60 cents a share, in the quarter, down from $1.9 ...
Promising Schizophrenia Drug, Cobenfy, Will Likely Face Access Challenges
Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...
Bristol Myers earnings beat expectations, driven by sales of older drugs
Bristol Myers Squibb reported a higher-than-expected third-quarter profit on Thursday, citing strong sales of established ...
The Associated Press on MSN5d
A promising schizophrenia drug showed mixed results. What does that mean for patients?
Some people who took a new schizophrenia drug for one year improved with only a few side effects, but many dropped out of the ...
Bristol-Myers raises outlook ahead of consensus after Q3 beat
Bristol-Myers Squibb (BMY) stock gained as the comany exceeded Q3 2024 financial forecasts, with strong revenue growth and ...
Bristol Myers Squibb stock rises, Merck moves lower. Here's why.
Pharmaceutical giant Bristol Myers Squibb (BMY) raises its full-year earnings guidance after topping third quarter estimates, ...
Bristol Myers Squibb's Q3 Earnings Are Likely To Be Strong
Expectations for Bristol Myers Squibb's Q3 results have significantly declined. Despite this, check out why I maintain a "Buy ...
FiercePharma5d
As new drugs deliver, Bristol Myers CEO looks to 'further improve productivity and efficiency'
Bristol Myers’ $1.5 billion restructuring initiative that runs through 2025 may not be the end of the company’s ongoing efficiency push.  | Bristol Myers' $1.5 billion restructuring initiative that ...
Bristol Myers price target raised to $60 from $55 at BofA
BofA raised the firm’s price target on Bristol Myers (BMY) to $60 from $55 and keeps a Neutral rating on the shares. Bristol reported ...